Core Insights - Fangzhou Inc. has appointed Mr. Wang Haijiao as the new CEO, effective March 26, 2026, succeeding former CEO Mr. Xie Fangmin [1][2] - The company reported a significant financial turnaround for fiscal year 2025, achieving a net profit of RMB12.0 million and a 30.2% year-over-year revenue increase to RMB3.53 billion [2] - Mr. Wang brings nearly 20 years of experience in the healthcare industry, with expertise in digital health and precision medicine, previously holding key positions at GTJA Investment Group and Dragon Rise Capital [3] Company Strategy and Vision - Mr. Wang emphasized the importance of leveraging Fangzhou's digital healthcare infrastructure and proprietary XS LLM to enhance care standards for millions of patients and support over 250,000 physicians [4][5] - The company aims to deepen its 'AI + CDM' strategy and continue executing its 'Medicine as a Service' (MaaS) model under Mr. Wang's leadership [4] - Fangzhou's recent initiatives include the launch of the multimodal "XingShi" Large Language Model (XS LLM) to improve user experience and diagnostic accuracy [5] Company Profile - Fangzhou Inc. is recognized as China's leading online chronic disease management platform, serving 56.4 million registered users and 251,000 physicians as of December 31, 2025 [6] - The company specializes in providing tailored medical care and AI-enabled precision medicine solutions [6]

（於開曼群島註冊成立的有限公司） （股份代號：6086） 董事名單及其角色與職能 方 舟 云 康 控 股 有 限 公 司（「本公司」）的 董 事 會（「董事會」）成 員 載 列 如 下： 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或 任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Fangzhou Inc. 方舟云康控股有限公司 ZHOU Feng先 生 （執行董事） 鄒宇鳴先生 （執行董事） 王海蛟先生 （執行董事） David McKee HAND先 生 （董事會主席及非執行董事） 謝方敏先生 （非執行董事） 王海忠博士 （獨立非執行董事） 康韋女士 （獨立非執行董事） 朱小路先生 （獨立非執行董事） 董事委員會 董 事 審核委員會 薪酬委員會 提名委員會 ZHOU Feng先 生 成 員 鄒宇鳴先生 王海蛟先生 David McKee HAND先 生 成 員 成 員 謝方敏先生 王海忠博士 成 員 成 員 康韋女士 成 員 主 席 成 員 朱小路先生 主 席 成 員 主 席 三個董事委員會各 ...

王先生的履歷詳情載列如下： 王先生，現年45歲，於2014年加入高特佳投資集團，曾擔任其副總經理、投 資委員會成員及執行合夥人。彼於醫療健康產業擁有近20年創業、管理及投 資經驗，專注領域涵蓋體外診斷（IVD）、精準醫藥及數字健康。在加入高特 佳投資集團前，王先生曾於2012至2014年間擔任龍騰資本投資總監。王先生 現亦擔任廣州安必平醫藥科技有限公司（股票代號：688393.SH）董事。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Fangzhou Inc. 方舟云康控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6086） 委任行政總裁及執行董事 方舟云康控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事 （「董事」）會（「董事會」）欣然宣佈，王海蛟先生（「王先生」）已獲委任為本 公司行政總裁（「行政總裁」）及執行董事，自2026年3月26日起生效。 王先生於2006年獲得復旦大學生命科學學院微生物學碩士學位。彼於201 ...

Financial Performance - Revenue for the year ended December 31, 2025, increased significantly by 30.2% to RMB 3.53 billion, driven by the continuous expansion of consumer-facing business segments [4]. - The company achieved a turnaround to profitability with a net profit of RMB 12.0 million, compared to a net loss in 2024 [4]. - Total revenue for the year increased by 30.2% to RMB 3.53 billion, up from RMB 2.71 billion in the previous year, primarily reflecting increases in online retail pharmacy services, wholesale, and integrated medical services [27]. - The net profit improved from a loss of RMB 854.9 million for the year ending December 31, 2024, to a profit of RMB 11.8 million for the year ending December 31, 2025 [47]. - Adjusted net profit for the year ending December 31, 2025, was RMB 20.4 million, compared to RMB 17.1 million for the year ending December 31, 2024 [52]. - Gross profit rose by 8.4% from RMB 515.9 million for the year ending December 31, 2024, to RMB 559.4 million for the year ending December 31, 2025 [36]. - Operating loss for 2025 was RMB 13,422 thousand, a significant improvement from a loss of RMB 777,693 thousand in 2024 [106]. - The company reported a basic earnings profit of RMB 10,856,000 for 2025, compared to a loss of RMB 854,885,000 in 2024 [147]. User Growth and Engagement - Average monthly active users grew by 35% to 13.7 million, with total registered doctors exceeding 251,000 by the end of the reporting period [4]. - The total number of registered users reached 56.4 million, with a repurchase rate exceeding 85% and prescription drugs accounting for over 80% of total transaction value [9]. - Online retail pharmacy service revenue increased significantly by 33.4% year-on-year to RMB 1.87 billion, driven by user growth and continuous innovation in user experience and technology [15]. - Online retail pharmacy services generated revenue of RMB 1,873,395 thousand in 2025, up 33.4% from RMB 1,404,790 thousand in 2024 [120]. Strategic Initiatives and Innovations - The integrated AI model "Xing Shi" was launched, incorporating multi-modal functions aimed at enhancing chronic disease management [4]. - The company has initiated pilot testing of AI digital doctors to assist in online consultations, combining the trust of human medical services with the scalability of digital delivery [12]. - Strategic partnerships were established with leading pharmaceutical companies to enhance the accessibility of innovative therapies in oncology and metabolic diseases [13]. - The company continues to focus on innovation and strategic partnerships to meet the growing demand for high-quality chronic disease management services [8]. - The introduction of AI technologies, including the "AI Content Creation Assistant," aims to enhance content creation speed and quality while reducing operational costs [17]. - The "Medical as a Service" (MaaS) strategy will guide the company towards a patient-centered operational model, enhancing platform capabilities to meet evolving customer and industry partner needs [22]. Financial Position and Assets - Total assets less current liabilities amounted to RMB 170,117 thousand in 2025, up from RMB 162,794 thousand in 2024 [109]. - The company reported a total equity of RMB 153,729 thousand in 2025, an increase from RMB 131,704 thousand in 2024 [112]. - Cash and cash equivalents increased from RMB 174.6 million as of December 31, 2024, to RMB 233.5 million as of December 31, 2025, indicating improved cash flow from operating activities [62]. - Trade receivables rose from RMB 36.3 million as of December 31, 2024, to RMB 61.8 million as of December 31, 2025, reflecting increased receivables due to business expansion in online social insurance payments [57]. - Inventory increased from RMB 141.4 million as of December 31, 2024, to RMB 180.4 million as of December 31, 2025, while the average inventory turnover period improved from 23.1 days to 19.8 days [56]. Cost Management and Expenses - Total sales cost increased by 35.4% to RMB 2,966.7 million for the year ending December 31, 2025, from RMB 2,191.4 million for the year ending December 31, 2024 [35]. - Sales and distribution expenses increased by 12.8% to RMB 401.2 million for the year ending December 31, 2025, from RMB 355.8 million for the year ending December 31, 2024 [39]. - Administrative expenses decreased by 83.8% to RMB 147.3 million for the year ending December 31, 2025, from RMB 909.5 million for the year ending December 31, 2024 [42]. - Financing costs decreased by 98.2% to RMB 1.4 million for the year ending December 31, 2025, compared to RMB 77.2 million for the year ending December 31, 2024 [45]. Shareholder and Capital Management - The company raised approximately HKD 144.30 million from the placement of 45,181,000 shares at a price of HKD 3.32 per share [84]. - About 90% or HKD 129.87 million of the net proceeds from the placement will be used to accelerate the development of an AI-driven chronic disease management platform [86]. - The company aims to expand its shareholder base and capital base through the placement and subscription [86]. - The company does not plan to declare any final dividends for the fiscal year ending December 31, 2025 [103]. Governance and Management - The board has appointed a new chairman and is in the process of searching for a new CEO following the resignation of the previous CEO [83][87]. - The company is committed to corporate governance as per the guidelines set out in the listing rules [171]. - The board of directors includes both executive and non-executive members, ensuring diverse oversight [178].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Fangzhou Inc. 方舟云康控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6086） 於本公告日期，董事會的成員包括執行董事 ZHOU Feng 先生及鄒宇鳴先生、 非執行董事 David McKee HAND 先生及謝方敏先生，以及獨立非執行董事 王海忠博士、康韋女士及朱小路先生。 董事會會議日期 執行董事兼聯席公司秘書 鄒宇鳴先生 香港，2026年3月9日 方舟云康控股有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將 於2026年3月19日（星期四）舉行董事會會議，藉以（其中包括）考慮及批准本 公司及其附屬公司截至2025年12月31日止年度業績及其發佈，並考慮派發末 期股息（如有），及處理其他事項。 承董事會命 方舟云康控股有限公司 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 方舟云康控股有限公司 呈交日期: 2026年3月2日 FF301 第 1 頁 共 10 頁 v 1.2.0 FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06086 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 1,340,267,457 | | 0 | | 1,340,267,457 | | 增加 / 減少 (-) | | | 45,181,000 | | 0 | | | | 本月底結存 | | | 1,385,448,457 | | 0 | | 1,385,44 ...

Core Viewpoint - Fangzhou Inc. has entered a strategic collaboration with Youcare Pharmaceutical Group to enhance chronic disease services through AI-driven solutions, aiming to support China's digital transformation in healthcare [1][2][8] Group 1: Partnership Objectives - The collaboration focuses on two main areas: co-development of digital systems for chronic disease management and expansion of health management services in key therapeutic areas [6][4] - The partnership aims to integrate Youcare's pharmaceutical expertise with Fangzhou's AI capabilities to create a digitally enabled chronic disease management system [6][4] Group 2: Industry Context - China's chronic disease management is shifting from a drug-centered model to a patient-centered approach, necessitating digital transformation in healthcare services [3][8] - The partnership aligns with China's "Healthy China 2030" initiative, emphasizing the importance of integrating AI technology with chronic disease services and pharmaceutical innovation [8][7] Group 3: Company Profiles - Fangzhou Inc. is a leading online chronic disease management platform in China, serving 52.8 million registered users and 229,000 physicians as of June 30, 2025, specializing in AI-enabled precision medicine [9] - Youcare Pharmaceutical Group is a large-scale conglomerate in the pharmaceutical industry, focusing on drug R&D, manufacturing, and distribution, and is recognized as one of the top 100 enterprises in China [10]

Core Insights - Fangzhou Inc. has been recognized at the "Digital Intelligence Powering Guangdong" 2026 Members Conference for its MaaS (Medicine as a Service) platform, which is seen as a model for the future of Internet healthcare [1][7] - The company was awarded the title of "2025 Distinguished Member Enterprise" for its long-term contributions to service-oriented healthcare delivery and its innovative AI + H2H Smart Healthcare Innovation Ecosystem [3][8] Company Overview - Fangzhou Inc. is a leading provider of AI-driven Internet healthcare solutions in China, focusing on chronic disease management and serving 52.8 million registered users and 229,000 physicians as of June 30, 2025 [9] - The company aims to address healthcare challenges such as resource imbalance and low service efficiency through technology-driven solutions [4] Technological Advancements - In 2025, Fangzhou upgraded its ecosystem to an "AI + H2H" model, enhancing service continuity and accessibility for patients [5] - The upgrade signifies a transformation in service delivery, moving beyond mere technology adoption to a comprehensive approach in chronic disease management [6] Strategic Direction - Fangzhou is committed to deepening the integration of innovative technologies with chronic disease management services, contributing to the sustainable development of China's digital healthcare industry [8]

Core Insights - Fangzhou Inc.'s "XingShi" Large Language Model (XS LLM) is recognized as one of the most anticipated healthcare AI models in China for 2026, according to VBData [1] - XS LLM integrates five intelligent agents into a closed-loop system for chronic disease management, attracting international attention [2] - The model is built on over 1.1 million articles from 170 core journals, providing significant clinical support with nearly 400,000 instances of assistance to physicians [3] Company Overview - Fangzhou Inc. is a leading online chronic disease management platform in China, with 52.8 million registered users and 229,000 physicians as of June 30, 2025 [9] - The company specializes in AI-enabled precision medicine solutions and aims to deepen AI integration in chronic disease services [7] Product Features - XS LLM powers five AI-enabled applications: AI Medication Finder, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI-Powered Search, addressing various clinical and patient-side use cases [4] - Each application facilitates real-time interventions in medication guidance, patient education, diagnostic assistance, and medical reference [4] Industry Context - Other notable AI models in the market include those from JD Health, Ant Group, and Tencent Health, which are increasingly optimized for China's clinical guidelines and regulatory requirements [6] - The industry is working towards ambitious national targets for the development of medical AI models by 2027 and aims for near-universal intelligent clinical assistance in primary care by 2030 [6]

Core Insights - The article highlights that Ark Health (HKEX: 06086) received the "Intelligent Future Award" at the T-Inspire CIO Private Meeting hosted by Tencent Health, indicating its leadership in chronic disease services and recognition in the healthcare industry's digital transformation [1][3] Group 1: Company Achievements - Ark Health stands out for its innovative technology applications and solid results in the internet healthcare sector, providing efficient, precise, and inclusive solutions [3][4] - The company has established a robust "Medicine as a Service" (MaaS) system, integrating patient trust with strong service capabilities to transform care for chronic diseases into scalable and actionable services [4][5] Group 2: Industry Impact - Ark Health's advancements are reshaping the value logic of chronic disease services by breaking traditional barriers of time and space, enhancing accessibility to quality medical resources [4][5] - The collaboration with Tencent Health has expanded new pathways for technology application, creating a closed loop from technical validation to practical implementation in chronic disease services [4] Group 3: Financial Performance - The company is expected to achieve a revenue of 3.5 billion to 3.55 billion yuan in 2025, reflecting a significant year-on-year growth of 30% [5] - The strong financial performance and the established "familiar doctor-patient" model indicate a promising long-term growth potential for the company [5]